ESTUTC-5 New YorkLog in Sign up

CMPX
Compass Therapeutics, Inc. Common Stock
stockNASDAQ

At CloseNov 13, 2026 3:59:32 PM EST

0.77USD-5.756%(-0.05)1,549,274

After-hoursNov 13, 2026 4:12:30 PM EST

0.774USD+0.155%(+0.001)

CMPX News

Day breaks

06:38 PM ESTCompass Therapeutics at Stifel 2026 Healthcare Conference 2026: FDA path in focus ·

Investing.com

11:05 AM ESTCMPX Maintained by Wedbush -- Price Target Lowered to $0.90 ·

GuruFocus

03:52 PM ESTCompass Therapeutics at Guggenheim conference: tovecimig faces FDA test ·

Investing.com

08:13 AM ESTCompass Therapeutics GAAP EPS of -$0.16 ·

Seeking Alpha

08:00 AM ESTCompass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update ·

GlobeNewswire Inc.

09:04 AM ESTCompass Therapeutics presents data on CTX-10726 mechanism ·

Investing.com

09:00 AM ESTCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting ·

GlobeNewswire Inc.

09:00 AM ESTCompass Therapeutics to Participate in Upcoming November Investor Events ·

GlobeNewswire Inc.

04:20 AM EDTCompass Therapeutics publishes tovecimig trial results in JCO ·

Investing.com

04:15 AM EDTCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 ·

GlobeNewswire Inc.

04:30 PM EDTCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ·

GlobeNewswire Inc.

08:31 AM EDTCompass Therapeutics CAO Neil Lerner buys $18,400 in company shares ·

Investing.com

08:15 AM EDTCompass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares ·

Investing.com

11:03 AM EDTCompass Therapeutics downgraded at Wedbush as FDA seeks additional trial for lead asset ·

Seeking Alpha

07:48 AM EDTH.C. Wainwright cuts Compass Therapeutics stock price target on FDA trial recommendation ·

Investing.com

05:18 AM EDTCitizens cuts Compass Therapeutics stock price target on FDA trial request ·

Investing.com

04:56 PM EDTWedbush downgrades Compass Therapeutics stock rating on FDA trial concerns ·

Investing.com

11:12 AM EDTCompass Therapeutics stock price target maintained at $6 by Stifel ·

Investing.com

09:02 AM EDTCompass Therapeutics drops as FDA seeks additional trial for lead asset ·

Seeking Alpha

08:30 AM EDTCompass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback ·

GlobeNewswire Inc.